KKR, the US private equity powerhouse actively pursuing acquisition targets amid ongoing market volatility, is weighing a potential buyout of Italian health-care technology company GPI SpA, according to a report by Bloomberg.
The buyout giant has engaged advisers in recent weeks as it evaluates a possible deal to take the Trent-based firm private, according to individuals familiar with the discussions who requested anonymity due to the confidential nature of the talks.
Following reports of the potential transaction, GPI’s shares surged as much as 6.9%, marking their highest level since February 2023. The stock has climbed approximately 27% in Milan trading this year, valuing the company at around €385m ($446m).
GPI’s largest shareholder is an investment vehicle controlled by CEO Fausto Manzana, holding a 48% stake and 57% of voting rights, per the company’s latest annual report.
While deliberations remain ongoing, there is no guarantee they will culminate in a deal, sources added. KKR declined to comment, and GPI’s representatives were similarly silent.
GPI provides a suite of digital solutions for the health-care sector, including hospital information systems, diagnostic tools, and care management technologies. In 2024, the company generated revenues of €510m, with EBITDA up 31% to €105m and net profit from continuing operations reaching €15m.
A successful acquisition of GPI would bolster a wave of European PE buyouts this year, as sponsors capitalise on improved financing conditions and attractive valuations. KKR, one of the region’s most active players, recently secured a £4.1bn deal for Spectris, outbidding Advent for the British precision testing equipment maker.
KKR’s founders confirmed in May that the firm is intensifying its search for opportunities beyond the US, with Europe a key focus. The firm has also closed multibillion-euro deals recently for Swedish consumer-health company Karo Healthcare and post-trade services provider OSTTRA.
